Mira Pharmaceuticals (MIRA) Enterprise Value (2022 - 2025)
Mira Pharmaceuticals (MIRA) posted Enterprise Value of -$11.0 million for Q4 2025, down 46.37% sequentially from -$7.5 million in Q3 2025, and down 289.35% YoY from $5.8 million in Q4 2024.
Mira Pharmaceuticals (MIRA) Enterprise Value (2022 - 2025) Analysis & Trends
Mira Pharmaceuticals has reported Enterprise Value for 4 years, with the latest figure at -$11.0 million in Q4 2025.
- Quarterly Enterprise Value fell 289.35% year-over-year to -$11.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$11.0 million (down 289.35% YoY) and the FY2025 annual result came in at -$11.0 million, down 289.35% from the prior year.
- Enterprise Value declined to -$11.0 million in Q4 2025 per MIRA's latest filing, from -$7.5 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$1349.0 in Q1 2023 and troughed at -$11.0 million in Q4 2025.
- A 4-year average of -$3.2 million and a median of -$2.8 million in 2024 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value tumbled 261478.58% in 2024, then jumped 65.81% in 2025.
- Over 4 years, Enterprise Value stood at -$350978.0 in 2022, then plunged by 1211.35% to -$4.6 million in 2023, then surged by 38.45% to -$2.8 million in 2024, then sank by 289.35% to -$11.0 million in 2025.
- According to Business Quant data, Enterprise Value over the past three periods registered -$11.0 million, -$7.5 million, and -$730475.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -20.76 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -6.52 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -7.09 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -7.69 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -4.90 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -13.99 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -3.26 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -11.40 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -4.80 Bn |
| 10 | Mira Pharmaceuticals | 18.47 Mn | 7.44 Mn | - | -11.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -11.03 Mn |
| Sep 30, 2025 | -7.54 Mn |
| Jun 30, 2025 | -730,475.00 |
| Mar 31, 2025 | -1.21 Mn |
| Dec 31, 2024 | -2.83 Mn |
| Sep 30, 2024 | -4.14 Mn |
| Mar 31, 2024 | -3.53 Mn |
| Dec 31, 2023 | -4.60 Mn |
| Sep 30, 2023 | -5.87 Mn |
| Jun 30, 2023 | -24,823.00 |
| Mar 31, 2023 | -1,349.00 |
| Dec 31, 2022 | -350,978.00 |
| Sep 30, 2022 | -187,415.00 |